Abstract: The present disclosure relates to a modular fastener gun comprising at least a gun body that can accept any number of fastener cartridges using a same connection assembly mechanism. In one example, a fastener cartridge comprises a fastener box used to hold fasteners, the fastener box including a first alignment structure and a second alignment structure, the first alignment structure used to detachably connect the fastener cartridge to a fastener gun body, and the second alignment structure used to lock the fastener cartridge to the gun body. In this way, a plurality of fastener cartridges that each can house different fastener types, can readily be used with a same fastener gun.

Abstract: The present invention provides a water surface cleaning machine, comprising a hull, a cleaning device provided at the bottom of the hull for collecting and storing water surface floating debris, a propulsion device provided at the front end and/or the back end of the hull for propelling the hull to travel on the water surface, a steering device provided at the corner portion between the front end and the side edge of the hull, wherein steering device causes the hull to rotate relative to an obstacle for adjusting traveling direction of the hull when the hull comes into contact with the obstacle during traveling on the water surface, and a power unit provided inside the hull for providing power to the propulsion device and the steering device.

Abstract: The present invention provides a rivet gun including a first handle, a second handle, a transmission mechanism, and a clamping-pulling mechanism.

Abstract: The present invention provides a water surface cleaning machine, comprising a hull, a cleaning device provided at the bottom of the hull for collecting and storing water surface floating debris, a propulsion device provided at the front end and/or the back end of the hull for propelling the hull to travel on the water surface, a steering device provided at the corner portion between the front end and the side edge of the hull, wherein steering device causes the hull to rotate relative to an obstacle for adjusting traveling direction of the hull when the hull comes into contact with the obstacle during traveling on the water surface, and a power unit provided inside the hull for providing power to the propulsion device and the steering device.

Abstract: The present invention provides a retractable cutting tool, which includes: a cutting tool housing, the interior thereof forming a cavity; a blade exit portal, penetrating through the cutting tool housing and communicating with the cavity; a blade holder, moved or locked in the cutting tool housing; a blade, mounted to the blade holder and disposed opposite the blade exit portal; when the blade holder is moved, the front end of the blade protrudes out of the cutting tool housing or retracts into the cutting tool housing through the blade exit portal; a blade holder moving device, for moving the blade holder in the cutting tool housing; and a protrusion length control device, for controlling the protrusion length of the blade outside the cutting tool housing.

Abstract: The present utility model discloses a utility knife with dual blades, comprising a housing having an opening at both ends, a blade carrier which is mounted and is movable within the housing, a movement assembly connected to the blade carrier for driving the blade carrier to respectively move in a direction towards both ends of the housing, wherein it further comprises a stop member. The blade carrier is provided with an abutment portion thereon, and the stop member has a stop portion being able to change its position with respect to the abutment portion, so that the blade carrier can move in a single direction so as to prevent the blade carrier from accidentally sliding and pushing the blade out to injure a user.

Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including an engineered attenuated vaccinia vims (VACV) strain comprising a disruption of the N-terminal DNA binding domain of the E3L gene (E3L?A83N) with a deletion of thymidine kinase (E3L?83N-TK?) engineered to express an antibody specifically targeting cytotoxic T lymphocyte antigen (E3L?83N-TK?-anti-CTLA-4), alone or in combination with immune checkpoint blocking agents or immune stimulating agents, as an oncolytic and immunotherapeutic composition. In some aspects, the present technology relates to an E3L?83N-TK?-anti-CTLA-4 virus further engineered to express human Fms-like tyrosine kinase 3 ligand (hFlt3L) (E3L?83N-TK?-hFlt3L-anti-CTLA-4).

Abstract: The present invention provides a power-assisted folding knife, comprising a handle, a blade, a locking mechanism, an assisting mechanism and a second assisting mechanism. The blade is rotatably connected to the handle. The locking mechanism and the second assisting mechanism are provided inside the handle. The assisting mechanism is connected to the handle and the blade respectively. When the blade is in a folded position, the assisting mechanism and the second assisting mechanism are used for locking or unlocking the blade. When the blade is in an unfolded position, the locking mechanism is used for locking or unlocking the blade. When the power-assisted folding knife is unfolded, the assisting mechanism and the second assisting mechanism provide assisting force for the blade and/or the handle.

Abstract: Disclosed is a manual tool capable of unfolding only one work accessory. The conventional manual tools may bring hidden risk to safety with more than two work accessories that may be unfolded simultaneously.

Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA?C7L and VACV?C7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA?C7L or VACV?C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

Abstract: The present invention discloses a connecting structure, a connecting method and an article containing the connecting structure. The connecting structure includes a fastener, a first connecting member adjacent to the trailing end of the fastener and a second connecting member away from the trailing end of the fastener. The second connecting member is provided with a threaded connecting hole, which in the axial direction thereof is provided with thread matching with the form of thread of the fastener and having a central angle of at least 180 degrees. The first connecting member is provided with a connecting hole, and the fastener connects the two connecting members through the threaded connecting hole and the connecting hole. The connecting method achieves quick connecting with the connecting hole of the first connecting member by preloading the fastener to the threaded connecting hole, without being affected by the assembly space.

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fins-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

Abstract: The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVA?E3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.

Abstract: The invention discloses a storage shelf, comprising upright posts (1) and transverse beams (2), and further comprising shelf boards (3), wherein first reinforcement ribs (4) are provided on the transverse beams; and the first reinforcement ribs can both reinforce the transverse beams and serve as supporting parts for the shelf boards, having a simple structure without reducing the strength of the transverse beams. The transverse beams and the upright posts are directly connected by way of clamping, and can be assembled and disassembled conveniently.

Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.